TY - JOUR
T1 - Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T-acute lymphoblastic leukemia
T2 - Long-term comparison of outcomes in the JACLS NHL T-98 and ALL T-97 protocols
AU - Kobayashi, Ryoji
AU - Takimoto, Tetsuya
AU - Nakazawa, Atsuko
AU - Fujita, Naoto
AU - Akazai, Ayumi
AU - Yamato, Kazumi
AU - Yazaki, Makoto
AU - Deguchi, Takao
AU - Hashii, Yoshiko
AU - Kato, Koji
AU - Hatakeyama, Naoki
AU - Horibe, Keizo
AU - Hori, Hiroki
AU - Oda, Megumi
PY - 2014/6
Y1 - 2014/6
N2 - T cell lymphoblastic lymphoma (T-LBL) accounts for 30% of all childhood non-Hodgkin's lymphomas (NHL) in Japan. Twenty-nine patients with T-LBL in stages III and IV were eligible for and enrolled in the JACLS NHL-T98 trial (1998-2002), and 72 patients with T-ALL were enrolled in the JACLS ALL-T97 trial (1997-2001). The 10-year overall survival (OS) (61.1 ± 11.5%) and the 10-year event-free survival (EFS) (44.4 ± 11.7%) of stage III LBL were lower than those of other diseases, and the OS and EFS were nearly the same when comparing stage IV LBL and ALL (OS: stage IV LBL, 80.0 ± 12.7% vs. ALL, 80.2 ± 4.9%; EFS: stage IV, LBL 70.0 ± 14.5% vs. ALL, 70.7 ± 5.5%). Outcomes were worse for stage III LBL than for stage IV LBL or T-ALL. Given that the treatment results of T-ALL and LBL stage IV did not differ when compared with previous reports, LBL stage III in Japanese children may differ from LBL stage III in children in other countries.
AB - T cell lymphoblastic lymphoma (T-LBL) accounts for 30% of all childhood non-Hodgkin's lymphomas (NHL) in Japan. Twenty-nine patients with T-LBL in stages III and IV were eligible for and enrolled in the JACLS NHL-T98 trial (1998-2002), and 72 patients with T-ALL were enrolled in the JACLS ALL-T97 trial (1997-2001). The 10-year overall survival (OS) (61.1 ± 11.5%) and the 10-year event-free survival (EFS) (44.4 ± 11.7%) of stage III LBL were lower than those of other diseases, and the OS and EFS were nearly the same when comparing stage IV LBL and ALL (OS: stage IV LBL, 80.0 ± 12.7% vs. ALL, 80.2 ± 4.9%; EFS: stage IV, LBL 70.0 ± 14.5% vs. ALL, 70.7 ± 5.5%). Outcomes were worse for stage III LBL than for stage IV LBL or T-ALL. Given that the treatment results of T-ALL and LBL stage IV did not differ when compared with previous reports, LBL stage III in Japanese children may differ from LBL stage III in children in other countries.
UR - http://www.scopus.com/inward/record.url?scp=84905242507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905242507&partnerID=8YFLogxK
U2 - 10.1007/s12185-014-1585-z
DO - 10.1007/s12185-014-1585-z
M3 - Article
C2 - 24803201
AN - SCOPUS:84905242507
SN - 0925-5710
VL - 99
SP - 743
EP - 749
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 6
ER -